Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 545 matching trials from the live ClinicalTrials.gov search.
Filters: Salt Lake City, Utah Clear all
Recruiting Phase 4 Interventional

A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

NCT04375033
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Sublingual buprenorphine with naloxone, Injectable subcutaneous buprenorphine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
25
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 30, 2026, 5:53 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

NCT01349322
View directory record Official record
Conditions
Breast Cancer
Interventions
Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost, Sequential boost
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
2,354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
386
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 304 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 30, 2026, 5:53 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

NCT03345836
View directory record Official record
Conditions
Crohn's Disease
Interventions
Matching Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
119
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 30, 2026, 5:53 PM EDT
Active, not recruiting Phase 1 Interventional

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity

NCT06577766
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NNC0638-0355, Placebo (NNC0638-0355)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 5:53 PM EDT
Recruiting Phase 3 Interventional

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

NCT03150693
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia
Interventions
Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis
Drug · Procedure · Biological + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 39 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
455
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 279 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

NCT03497806
View directory record Official record
Conditions
Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff, CDI, Recurrent C. Diff, rCDI, C. Difficile, Recurrent CDI, FMT, Fecal Microbiota, Fecal Transplant
Interventions
CP101
Biological
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
53
States / cities
Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 30, 2026, 5:53 PM EDT
Terminated Phase 2 Interventional Results available

S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia

NCT00053014
View directory record Official record
Conditions
Leukemia
Interventions
therapeutic allogeneic lymphocytes, cyclosporine, fludarabine, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
55 Years to 69 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
83
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 30, 2026, 5:53 PM EDT
Active, not recruiting Phase 3 Interventional

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

NCT03267433
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human
Procedure · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years to 70 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
374
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 236 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 5:53 PM EDT
Terminated Phase 2 Interventional

S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases

NCT00003911
View directory record Official record
Conditions
Melanoma (Skin), Metastatic Cancer
Interventions
stereotactic radiosurgery
Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
86
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 30, 2026, 5:53 PM EDT
Completed Phase 2 Interventional

S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer

NCT00003549
View directory record Official record
Conditions
Neuroendocrine Carcinoma of the Skin
Interventions
CMF regimen, cyclophosphamide, fluorouracil, methotrexate
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 30, 2026, 5:53 PM EDT
Active, not recruiting Not applicable Interventional

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

NCT02194738
View directory record Official record
Conditions
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7,458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1655
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Results available

Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer

NCT01236547
View directory record Official record
Conditions
Thyroid Gland Anaplastic Carcinoma
Interventions
Intensity-Modulated Radiation Therapy, Paclitaxel, Pazopanib Hydrochloride, Placebo Administration
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
130
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 30, 2026, 5:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

NCT05139121
View directory record Official record
Conditions
Contraception
Interventions
MR-100A-01
Drug
Lead sponsor
Mylan Technologies Inc.
Industry
Eligibility
16 Years and older · Female only
Enrollment
1,320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
96
States / cities
Mobile, Alabama • Mesa, Arizona • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 5:53 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

NCT07218354
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
622 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
19
States / cities
Long Beach, California • Palo Alto, California • West Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 30, 2026, 5:53 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Premature Fatigue in Veterans With Heart Failure: Neuronal Influences

NCT02209610
View directory record Official record
Conditions
Heart Failure
Interventions
Electrical and Magnetic Nerve Stimulators, Intrathecal Fentanyl
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 30, 2026, 5:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

NCT06015282
View directory record Official record
Conditions
Influenza, Human
Interventions
Investigational aQIVc, licensed QIVr, licensed aQIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years and older
Enrollment
7,741 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
51
States / cities
Tempe, Arizona • Little Rock, Arkansas • Huntington Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 30, 2026, 5:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program

NCT02673255
View directory record Official record
Conditions
Healthy
Interventions
Tetanus and Diphtheria (Td) Vaccine
Biological
Lead sponsor
Biomat USA, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
4
States / cities
Bellflower, California • Lincoln, Nebraska • Clarksville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 30, 2026, 5:53 PM EDT
Completed Phase 2 Interventional

S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach

NCT00004233
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
fluorouracil, leucovorin calcium, triacetyluridine
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
97
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 30, 2026, 5:53 PM EDT
Recruiting Phase 3 Interventional

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

NCT03937635
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
742
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 490 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 5:53 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

NCT03006068
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Upadacitinib (ABT-494), Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 75 Years
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
147
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 30, 2026, 5:53 PM EDT
Completed Phase 3 Interventional

S9630, Medroxyprogesterone in Treating Women With Breast Cancer

NCT00002920
View directory record Official record
Conditions
Breast Cancer, Endometrial Cancer
Interventions
medroxyprogesterone, tamoxifen citrate, adjuvant therapy
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
122
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 30, 2026, 5:53 PM EDT
Completed Phase 2 Interventional

S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

NCT00003784
View directory record Official record
Conditions
Lymphoma
Interventions
CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, tositumomab and iodine I 131 tositumomab
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
87
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 30, 2026, 5:53 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

NCT06417775
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant, Placebo for Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
103
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 30, 2026, 5:53 PM EDT
Terminated Phase 3 Interventional Results available

Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer

NCT00303628
View directory record Official record
Conditions
Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer
Interventions
oxaliplatin, fluorouracil, leucovorin calcium, bevacizumab
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
600
States / cities
Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 386 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 30, 2026, 5:53 PM EDT